Matthew B. Au
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Matthew B. Au has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
- Anne Plunkett
Department of Medicine/Section of Rheumatology, Boston University, Massachusetts, USA
1 shared publication - Carla R. Scanzello
VA CReATE Motion Center Corporal Michael J. Crescenz VA Medical Center Philadelphia Pennsylvania USA
1 shared publication - David T. Felson
Section of Rheumatology, Boston University School of Medicine, Boston, Massachusetts, USA
1 shared publication - Devyani Misra
Division of Rheumatology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, USA; Division of Geriatrics, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, USA
1 shared publication Eric J. Rubin
Department of Immunology and Infectious Diseases, Harvard School of Public Health, Boston, MA, USA
1 shared publicationErik C. Hett
Department of Immunology and Infectious Diseases, Harvard School of Public Health, Boston, MA, USA
1 shared publication
Latest Publications
- Open Access
- 3 September 2019
- Published by AVES YAYINCILIK A.Ş. in European Journal of Rheumatology
- Vol. 7 (1) , 44-45
Correlation between senescence-associated secretory phenotypes factors in synovial fluid and serum and structural changes in osteoarthritis
Cite this article as: Rubio JE, Scanzello C, Felson DT, Au MB, Goggins J, Plunkett A, et al. Correlation between senescence-associated secretory phenotypes factors in synovial fluid and serum and structural changes in osteoarthritis. Eur J Rheumatol 2020; 7(1): 44-5.
- 3 September 2019
- Published by AVES YAYINCILIK A.Ş. in European Journal of Rheumatology
- Vol. 7 (1) , 44-45
Open AccessCorrelation between senescence-associated secretory phenotypes factors in synovial fluid and serum and structural changes in osteoarthritis
Cite this article as: Rubio JE, Scanzello C, Felson DT, Au MB, Goggins J, Plunkett A, et al. Correlation between senescence-associated secretory phenotypes factors in synovial fluid and serum and structural changes in osteoarthritis. Eur J Rheumatol 2020; 7(1): 44-5.
- 2 January 2019
- Published by Springer Nature in Current Microbiology
- Vol. 76 (4) , 398-409
Cell Wall Hydrolytic Enzymes Enhance Antimicrobial Drug Activity Against Mycobacterium
Cell wall hydrolases are enzymes that cleave bacterial cell walls by hydrolyzing specific bonds within peptidoglycan and other portions of the envelope. Two major sources of hydrolases in nature are from hosts and microbes. This study specifically investigated whether cell wall hydrolytic enzymes could be employed as exogenous reagents to augment the efficacy of antimicrobial agents against mycobacteria. Mycobacterium smegmatis cultures were treated with ten conventional antibiotics and six anti-tuberculosis drugs—alone or in combination with cell wall hydrolases. Culture turbidity, colony-forming units (CFUs), vital staining, and oxygen consumption were all monitored. The majority of antimicrobial agents tested alone only had minimal inhibitory effects on bacterial growth. However, the combination of cell wall hydrolases and most of the antimicrobial agents tested, revealed a synergistic effect that resulted in significant enhancement of bactericidal activity. Vital staining showed increased cellular damage when M. smegmatis and Mycobacterium bovis bacillus Calmette–Guérin (M. bovis BCG) were treated with both drug and lysozyme. Respiration analysis revealed stress responses when cells were treated with lysozyme and drugs individually, and an acute increase in oxygen consumption when treated with both drug and lysozyme. Similar trends were also observed for the other three enzymes (hydrolase-30, RipA-His6 and RpfE-His6) evaluated. These findings demonstrated that cell wall hydrolytic enzymes, as a group of biological agents, have the capability to improve the potency of many current antimicrobial drugs and render ineffective antibiotics effective in killing mycobacteria. This combinatorial approach may represent an important strategy to eliminate drug-resistant bacteria.
- 2 January 2019
- Published by Springer Nature in Current Microbiology
- Vol. 76 (4) , 398-409
Cell Wall Hydrolytic Enzymes Enhance Antimicrobial Drug Activity Against Mycobacterium
Cell wall hydrolases are enzymes that cleave bacterial cell walls by hydrolyzing specific bonds within peptidoglycan and other portions of the envelope. Two major sources of hydrolases in nature are from hosts and microbes. This study specifically investigated whether cell wall hydrolytic enzymes could be employed as exogenous reagents to augment the efficacy of antimicrobial agents against mycobacteria. Mycobacterium smegmatis cultures were treated with ten conventional antibiotics and six anti-tuberculosis drugs—alone or in combination with cell wall hydrolases. Culture turbidity, colony-forming units (CFUs), vital staining, and oxygen consumption were all monitored. The majority of antimicrobial agents tested alone only had minimal inhibitory effects on bacterial growth. However, the combination of cell wall hydrolases and most of the antimicrobial agents tested, revealed a synergistic effect that resulted in significant enhancement of bactericidal activity. Vital staining showed increased cellular damage when M. smegmatis and Mycobacterium bovis bacillus Calmette–Guérin (M. bovis BCG) were treated with both drug and lysozyme. Respiration analysis revealed stress responses when cells were treated with lysozyme and drugs individually, and an acute increase in oxygen consumption when treated with both drug and lysozyme. Similar trends were also observed for the other three enzymes (hydrolase-30, RipA-His6 and RpfE-His6) evaluated. These findings demonstrated that cell wall hydrolytic enzymes, as a group of biological agents, have the capability to improve the potency of many current antimicrobial drugs and render ineffective antibiotics effective in killing mycobacteria. This combinatorial approach may represent an important strategy to eliminate drug-resistant bacteria.